Une entreprise spécialisée dans le développement de thérapies transformatrices ayant un impact sur la longévité. Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Children with rare diseases deserve therapeutic answers ORPHELIA Pharma is a French pharmaceutical company based in Paris and Lyon that develops and markets medicines for the treatment of pediatric orphan diseases. ORPHELIA Pharma‘s mission is to provide patients with essential products in the fields of epilepsy and pediatric oncology, with formulations adapted to the pediatric population. With one drug approved in the European Union and one product in late-stage clinical development, ORPHELIA Pharma has recently established regional agreements in the European Union, the USA and China and conducts research projects through academic and industrial partnerships. Neurology, Pediatry, Orphan drug, and …

14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

"Innovative medicine for everyone, everywhere"​ "Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/ Therapeutic proteins, BioChaperone®, Next-generation injectables for diabetes treatment, Ultra-rapid Insulin, Multi-agents injectable combination, Diabetes, Metabolic …

46 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

93 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

345 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

162 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

27 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

New Natural & Ethical Anti Inflammatory Pharmaceutical Products Natural Products with Proven Health Claims For PETS. Pomega develops a novel, safe, ethical and non-toxic therapy that retards disease progression by inhibiting cartilage breakdown at an earlier stage. Product is developed by skilled pharmacist under drug standards frame First product coming out the pipeline is Ω-344 Product , a patented fruit extract with strong anti inflammatory properties osteoarthritis , anti inflammatory, fruit extract, inflammation, arthritis, biotech, NSAIDs, pain, animal, dogs, pets, wellness, healthcare, petfood, and cats

11 similar entities Type: Startup Activities: pettech deeptech biotech Technologies: Synthetic Biology

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

64 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Marine-inspired molecules to fight immunological diseases. Traumatic brain injury is the #1 cause of death in people under 30. Yet no therapy today addresses the immune collapse that follows severe trauma. Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to restore immune function and improve recovery after trauma. Founded in 2019 and supported by four patents, we combine cutting-edge immunology and biotechnology to pioneer the field of post-traumatic immune restoration. Biotechnologie, immunologie, antibiorésistance, and commotions

61 similar entities Type: Startup Activities: deeptech biotech

CRO specialized in real-life data Kappa Santé was born from the desire to provide quality services in the fields of epidemiology, pharmacoepidemiology and public and digital health interventions. The company was founded at the end of 2002 and is based in Paris Kappa Santé is an independent CRO, member of ENCEPP (European Network of Centers for Pharmacoepidemiology and Pharmacovigilance), AFCRO (French Association of CROs), Oséo Excellence (community of entrepreneurs chosen by Oséo) and the Cap digital competitiveness cluster. We have now participated in more than 100 studies in numerous therapeutic areas Public health, Pharmaco-epidemiology, Medical devices, Intervention studies, Scientific communication, …

Type: SMB Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Danish biotech company developing peptide-small molecule drugs for treatment of obesity Ousia Pharma is a biotech spin-out from the University of Copenhagen developing novel peptide-drug conjugates for treatment of obesity and metabolic diseases. The company uses a proprietary targeting approach in which peptides are used to deliver modulators of synaptic plasticity to drive a potent and sustained weight loss without compromising safety. A main objective of Ousia Pharma is to advance the development of the lead weight loss drug candidate (OP-56) within general obesity.

13 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

We develop breakthrough medicines for patients through precision small molecule design. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases. …

49 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. Research, Innovation, Technology, In-vitro, 3D Cell Culture, Organ-on-Chip, Respiratory diseases, Drug Development, Drug Discovery, Preclinical Services, Safety, Efficacy, …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

410 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

95 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We deliver solutions AdhexPharma is an independent drug delivery company specialized in Transdermal & Topical patches and Oral Thin Films technologies. AdhexPharma is based in France, with GMP manufacturing facility for European and US market. We have 4 approved products in Europe and North America and a pipeline of 6 candidates, ranging from 505(b)2 / NDA and ANDA in different therapeutical areas: pain, CNS, anesthesia, smoking cessation and HRT. Trandermal, Patch, Oral Thin Film, Drug Development, GMP manufacturing, FDA approved, OTF, ODF, cGMP, TDS, CDMO, and CMO

55 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery Fueled by Ultra-Sensitivity Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research …

85 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

The extension of the pharmacist to support good nursing practices DrugOptimal offers software, an extension of the pharmacist, deployable in service to caregivers in order to avoid physicochemical drug incompatibilities (IPC) by detecting risks on the prescription and proposing administration solutions to avoid them. Database of 105,000 couples, validated, and developed from a compilation of 22,000 scientific articles, an IPC prediction model by AI (+4000 physico-chemical parameters per couple) and our own analytical chemistry research laboratory (dedicated high-throughput platform allowing the analysis of more than 1000 samples per day). Our scope of action: - Injectable drugs: support for the choice …

36 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Transform vaccine industry with reliable, stable, needle-free vaccines Vaxinano is a clinical-stage biotechnology company, developing a new generation of nasally administered vaccines that are more efficient and faster to deploy to combat infectious diseases and new pandemics. The vaccine is based on STELLAR-NP nanoparticles that confer highly stable, adjuvant-free solution for an effective and long-lasting response tot protect against the most difficult pathogens, such as parasites, viruses or bacteria... Biotechnology, Nanotechnology, Vaccine, Animal Health, and Human Health

52 similar entities Type: Startup Activities: biotech manufacturing Technologies: Bio sourced materials

Innovation for your health and well-being. Pharmaceutical company, R&D oriented dedicated to the development and marketing of senolytic compounds, food supplements and drugs against aging, age-related degenerative diseases and cancer.

98 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Interventions for Human Diseases Venture-funded company, discovering and developing oral novel small molecule first-in-class inhibitors of Bach1 (a transcription factor) as transformative potential therapy, globally accessible for patients with sickle cell disease (SCD), renal, cardiometabolic and neurodegenerative and other diseases. Sickle Cell Disease, fetal hemoglobin induction, beta-thalassemia, Renal diseases, cardiometabolic diseases, and neurodegenerative diseases

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

145 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We have developed a biological drug SOL-116 for treatment of chronic inflammatory diseases Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs. Inflammatory diseases, Drug development, Preclinical research, Blockbuster drugs, Chronic diseases, and Orphan drug designation

34 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Your partner in uro-genital pre-clinical research UROSPHERE is a leading Contract Research Organization specializing in preclinical urogenital, gastro-intestinal and oncological pharmacology studies. We provide the pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo models and in vitro assays on human and animal tissues. Innovation, Uro-genital pathologies, Oncology, PDX models, Organoids, CRO, Preclinical Research, Pharmacology, Drug development, Gastrointestinal pathologies, Experimental models, Pain, and Inflammation

118 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Clinical-stage biotech company transforming how disease is treated through targeted protein degradation science C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve …

47 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Specializing in the valorization of microalgae, Algobiotech is involved in the selection of new strains and the extraction of molecules of interest until their exploitation in cosmetic, food supplement and therapeutic applications. Algobiotech aims to develop and market innovative products derived from microalgae for the aforementioned applications. Through its membership of GENOPOLE, the leading French bio cluster in biotechnology, Algobiotech benefits from a very favorable environment for finding the right scientific and institutional partners to develop its R&D program around the identification and validation of the biological activities of molecules derived from micro-algae. Drawing on its intellectual property, the know-how, …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The synthetic collagen revolution NVH Medicinal world expert in synthetic collagen NVH Medicinal is a biotechnology company based in Dijon, created at the end of 2008, whose mission is based on the treatment of pathologies linked to a collagen deficiency. It develops products derived from collagen, the most abundant protein in the body and whose dysfunctions cause numerous diseases (aging, cardiovascular, inflammatory, neurological diseases, fibrosis, cancer and rare diseases). NVH's ambition is to be recognized as an innovative player in the treatment of collagen-related diseases by becoming one of the world leaders in the development, production and marketing of a …

59 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Your CDMO for API solutions since 1970 | Our excellence, your trust #OEYT At Seratec, APIs are more than a science. They are a passion. Entrepreneurs in pharmaceutical chemistry since 1970, we produce active pharmaceutical ingredients (APIs) for the treatment of rare and orphan diseases. Drawing on internationally recognized French know-how, we design, develop, produce and register files for pharmacologically active molecules with the American (FDA), European (EMA) and national (ANSM) drug agencies. To offer the best services, we also ensure the production of APIs according to quality standards known as Good Manufacturing Practices (GMP 2 or cGMP). The pharmaceutical …

58 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space. synthetic biology, RNA design, immunotherapy, covid-19, cancer, and mRNA therapy

96 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering science for patient choice Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dicot is a pharmaceutical company focused on increasing well-being through innovations that enhance sexual health. Dicot is a pharmaceutical company focused on increasing quality of life and well-being through innovations that enhance sexual health. The company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead candidate, LIB-01, is in clinical stage of development. erectile dysfunction, biopharma, premature ejaculation, drug development, pharma, sexual health, lifestyle , drug discovery, lifestyle, drug discovery, drugs from nature, and biopharmaceutical

18 similar entities Type: Startup Activities: manufacturing deeptech biotech healthtech Technologies: Synthetic Biology

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid

310 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

We supply the world with active pharmaceutical ingredients Farmabios is a leading global manufacturer of highly potent active pharmaceutical ingredients. With decades of steroid and complex chemistry expertise, and newly opened research and development projects in various fields, Farmabios provides bespoke products and solutions, understanding customer needs. Steroids, Chemistry, Active Pharmaceutical Ingredients, Hormones, Drug Substances, Healthcare, Pharmaceuticals, and Bespoke products

53 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

BIONEEDS INDIA PRIVATE LIMITED is a Bangalore based Contract Research Organization providing Integrated Discovery, Development and Regulatory Services to Pharmaceutical, Biopharmaceutical, Agrochemical, Industrial chemical, Herbal/Nutraceutical and Medical device companies. Accreditation/Certifications • National GLP Compliance Monitoring Authority (NGCMA), Dept. of Science and Technology, Government of India • Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment, Forests and Climate Change, GOI. • State Drug Controller as a Government approved Drug Testing Laboratory for carrying out tests on Drugs / Cosmetics and • Raw Materials used in their manufacture on behalf of licensees for manufacture …

99 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Targeting Chronic Pain Algonist Biotechnologies is a pre-clinical stage biotechnology company, developing novel small molecule therapeutics for chronic pain. Our mission is to develop drugs with similar potency to opioids but without leading to addiction.

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

110 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

547 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

197 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your safety passport for cosmetic ingredients & drug candidates Your partner for toxicological risk assessment requests Using our digital solutions increases the product safety and reduces the product development cost up by 30%. Insight Biosolutions (IBS) with his expert network has developed specialized platforms for in vitro and in silico services. IBS develops digital tools and services for the cosmetics and pharmaceutical industries. Computational Toxicology, in vitro toxicology , Safety assessment, Drug Discovery, Molecular Modeling, Computational Chemistry, CPSR, Pre Clinical screening, ADME, and PBPK

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

CORAL BIOME PHARMA Live cultured corals for Drug discovery Coral Biome is a research and development company dedicated to the discovery of marine natural products of interest for major public health issues such as cancer, inflammation and multi-drug resistant infectious diseases. Our multidisciplinary team of research and worldwide network of collaborators gathers a unique set of competitive expertise including, aquaculture, marine biology, chemistry, cell biology and cancerology to successfully isolate marine natural products and test their biological activity. We maintain a large-scale untapped reservoir of coral species to preserve endangered species, sell corals for aquarium trade (http://www.coralbiome.com/aquaculture/) and provide research …

18 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. With over a decade of expertise, Axol partners with global pharmaceutical companies, contract research organizations (CROs), biotechnology firms, start-ups, and academic institutions to advance the use of iPSC-based models in drug discovery and disease research. We operate across five key areas, neuroscience (including ALS, Alzheimer’s, Huntington’s, Parkinson’s, neuroinflammation), pain & sensation, ophthalmology (Dry-AMD, ophthal-inflammation), dermatology, and cardiovascular. Axol offers scalable solutions including iPSC banking, reprogramming, gene editing, cell manufacturing, and quality …

48 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Natural molecule discovery, industrialized Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation. genomics, synbio, and microbiology

95 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers

55 similar entities Type: Startup Activities: biotech deeptech

Innovative medicines to address haemato-oncology related life-threatening and rare diseases ElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases. Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs. Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Anticorps thérapeutiques, Anticorps monoclonaux, Therapeutic antibodies, Monoclonal antibodies, ophtalmologie, immune microenvironment, vascular …

43 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

45 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From Sea to Pharmacy ManRos Therapeutics is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors for the treatment of cystic fibrosis. ManRos was founded in 2007 and is led by Dr Laurent MEIJER, Chairman and CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de Lavenne, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Drug Development, Cystic Fibrosis, and Biotechnology

47 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production …

37 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Driven by the heart We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease. For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

357 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the power of NIK to transform the future of cancer and autoimmune disease treatment Nikaia Pharmaceuticals, an innovative company dedicated to the discovery and development of cutting-edge therapeutic solutions to improve patients' lives. 🔬💊 Our mission is to push the boundaries of science to deliver novel and effective treatments, focusing on the NIK protein (NF-κB-inducing kinase) and developing molecules capable of blocking its action.

52 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design. Most advanced product of the company are treatments for glaucoma and dry eye syndrome. Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com) Gene Sinlencing, siRNA RNAi Drugs, Ophtalmology, Biotechnology, RNAi, R&D, Pharmaceuticals, Bioinformatics, Biotecología, Biotech, Experimental drugs, Glaucoma, Dry eye syndrome, Target Therapies, Production, eyes diseases, RNAi Clinical Trials, Ophthalmology, Licensing, Research, Drug Discovey, and Rational Design

Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop a novel class of medicines with potential to transform the lives of patients with immune mediated diseases. We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function and fate coupled to a biomarker discovery effort with potential to bring precision to the treatment of immune-mediated diseases. Launched in 2018 by Third Rock Ventures with a $60 million Series A financing, Rheos is built on groundbreaking science from pioneers in the field, our passionate team of …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The future of women's health therapeutics is here. Celmatix Therapeutics is a preclinical-stage women’s health biotech focused on advancing groundbreaking therapeutics for women’s health. With its growing pipeline of innovative drug programs including an AMHR2 agonist program focused on ovarian aging, an oral FSH for infertility, and a JNK inhibitor program for endometriosis, Celmatix Therapeutics is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in women’s health. For more information, visit the company’s website at www.celmatix.com. Reproductive Biology and Medicine, Genomics, Bioinformatics, Biotech, Women's health, and Drug Development

47 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Changing the paradigm of osteoarthritis treatment! CartilaGen Inc. is developing an intra-articular injection of a small-molecule drug capable of preventing post-traumatic osteoarthritis. CartilaGen's solution aims to provide an unprecedented disease-modifying treatment to an area of medicine that remains an unmet medical need. Osteoarthritis, Biomaterials, and Preventative Medicine

52 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

AOBiome is focused on transforming human health by developing microbiome-based therapies for inflammatory conditions. AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rebalancing the immune system, resolving inflammation. Drug candidates from our molecular platforms normalize the immune system by downregulating pro-inflammatory immune response and upregulating regulatory immune response. IMD-Pharma S.A.S is a french biotechnology company conducting research and development of innovative drug candidates for immune-related inflammatory diseases. Founded in 2016, IMD-Pharma is a company from the Laboratoire de Chimie de Coordination (CNRS) and the Centre de Physiopathologie de Toulouse Purpan (INSERM/CNRS/Université Toulouse III). immuno-modulation, anti-inflammatory drugs, chronic inflammatory diseases, Multiple Sclerosis, Rheumatoid Arthritis, dendrimers, monocyte rehabilitation, and psoriasis

39 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

180 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing peptides for the treatment of rare endocrine and related diseases Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, …

4 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From lab to life mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South …

87 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the therapeutic potential of AAT AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The first product candidate is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.

50 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

OneHealth/AI DeepTech discovering patentable mixes of natural ingredients preserving health and optimizing bioprecesses Alphanosos, a Green One-Health DeepTech company, uses its own Artificial Intelligence algorithms to discover, develop and market active ingredients and products based on blends of extracts from non-pharmaceutical ingredients, in particular edible plants. These active mixtures, some of which are already patented in 15 countries for their antimicrobial activities, are intended for the animal hygiene, dermocosmetics, food preservation and cosmetics sectors, bioprocess optimization and in the longer term, for functional foods and disease treatments. The company began its Research and Development (R&D) activities in mid-2015 and is …

111 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Exploring together! We support biopharmaceutical research with translational preclinical models. CYNBIOSE is France-based non-clinical research organization. Preclinical CRO, Pharmacokinetics, POC, Efficacy, Immunotherapies, Drug, Early tox, CNS, Infectious diseases, Respiratory diseases, Non clinical, CRO, PK, PD, and TK

52 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its …

246 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Servier Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers. oncology, immune-evasive, and AXL

73 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases. BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company headquartered in Durham, North Carolina. Our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, …

69 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Built around safe-by-design concept, Adjuvatis is committed for innovative formulations to improve pharmaceuticals Adjuvatis, a French startup in biotechnology, develops innovative safe-by-design delivery systems to help laboratories and pharmaceutical companies in vaccine formulation as adjuvants and in drug delivery as vectors for oncology, dermatology, infections, etc. Our first technology, called i-Particles®, is based on 200 nm-diameter particles composed of poly-lactic acid only (any surfactant and solvents) for formulation of hydrophobic molecules in the particle core and surface functionalization of peptides. Our second technology, i-LipoP®, consists in i-Particles® covered by lipidic bilayers at their surface for vectorization of nucleic acids and …

38 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

First-in-class immunomodulatory peptides. Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need. immunodermatology, peptides, inflammatory diseases, respiratory diseases, inflammation, and immunomodulation

48 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

CRO specialized in pharmaceutical drugability for research Expertise in Human and Animal health solid form characterization and formulation development. We deliver both experimental support and consulting services to biotechnology and pharmaceutical companies, not-for-profit organizations and complementary CROs. We are member of the association AFSSI, 1st French research center in Life Sciences, as a founding member and member of the board of Directors. Since March 2019 Joel Vacus, Drugabilis CEO & CSO, is vice-President of AFSSI. https://www.afssi.fr/ Feel free to contact us in order to exchange about your preclinical drug development! contact@drugabilis.com Lead optimization, Formulation, and Physical form optimization

50 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing cell therapy for inflammatory diseases via neonatal cardiac progenitor cells and their secretomes Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

271 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antibody Targeted Biologics atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovative start up developing monoclonal antibodies in cancer and inflammatory diseases MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués

114 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

404 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The cosmetic expertise from the ingredient to the finished product Specialized in the assessment of finished cosmetic products, ingredients and cosmetic raw materials, we perform tolerance and efficacy studies. BIO-HC in-vitro : toxicological and pharmacological tests on cell models (primary cells, cell lines) and tissue models (epidermis, skin reconstructed in vitro). In vitro tests, GLP studies, and OECD tests

52 similar entities Type: SMB Activities: biotech deeptech cosmetics Technologies: Synthetic Biology

QIMA Life Sciences (formerly Bioalternatives, Synelvia, Newtone Technologies and Monasterium Laboratory) is a Contract Research Organization (CRO) specializing in cellular and molecular pharmacology. We offer assays ranging from in silico screening to non-invasive clinical sample bioanalysis, as well as in vitro and ex vivo assays. QIMA Life Sciences contributes to the development of in vitro methods, by offering solutions dedicated to preclinical research and to the development of drug candidates and to cosmetic active ingredients and formulations. QIMA Life Sciences can assist the health industry with its new strategic choices and helps the marketing and R&D departments to innovate in …

33 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotech Company 100% Focused on Pediatric Cancer Drug Development A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

291 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. AlmeeTM (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. …

19 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to the development of novel therapies to improve the lives of patients with respiratory disease Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. …

Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Customized phage therapies to eradicate harmful bacteria in chronic diseases BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. Microbiome, Biotechnology, Drug Discovery, Phage Therapies, and Pharma

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneers in complex formulation · Ascil Biopharm is a clinical-stage biotechnology company specializing in innovative drug delivery solutions. We operate as a CDMO, fully equipped for early-stage drug product development, with a GMP facility for clinical batch manufacturing, (aseptic process and terminal sterilization) to fill various containers (e.g. vials, syringes). Our capabilities extend to formulation, device, and analytical development. · Our proprietary Controlled-Release Formulation (CRF) platform technology, is designed to improve the Phy-Chem properties of APIs and excipients under injection conditions, enabling the development of ready-to-use (RTU) controlled-release formulations and ultra-high concentration (UHC) drug products. · Our expertise covers a …

60 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

Our mission is to discover, develop and deliver next generation cancer therapies. G1 Therapeutics, Inc. is a wholly owned subsidiary of Pharmacosmos. Cancer / Oncology, Drug Discovery and Development, and Biotechnology

148 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Delta4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta4 is driving the forefront of digital drug discovery and development. We leverage a proprietary computational analytics platform "Hyper-C", combining straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects. drug repositioning, drug discovery, compounds, orphan diseases, indication expansion, AI, and omics

55 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Reimaging known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery and development of novel therapeutics targeting transcription factors in cancer and other diseases QUANTRO Therapeutics (“QUANTRO”) is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute …

50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Therapeutics for the Diseases of Aging Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases Oncology, Aging, Dark Genome, ALS, Diabetes, and Longevity

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

152 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Igyxos develop more effective/efficient infertility treatment for patients Igyxos is a biotechnology company based out of CENTRE INRAe VAL DE LOIRE SITE DE TOURS, NOUZILLY, France. Biotechnologie, Fertilité, and anticorps monoclonal

196 similar entities Type: SMB Activities: biotech healthtech Technologies: Synthetic Biology

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective …

Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Science Driven Development and Analytical Support - From Early Development to Commercialization. Coriolis Pharma is a globally operating and science driven contract research and development organization (CRDO). We support drug product development of biopharmaceuticals, including gene and cell therapies and vaccines, from early development to commercialization. Our focus lies on formulation development, lyophilization technologies and analytics (GMP and non-GMP) for a wide range of products. As a privately held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients. We offer a large …

89 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology